临床与病理杂志2017，Vol.37Issue(8)：1629-1633,5.DOI:10.3978/j.issn.2095-6959.2017.08.014
贝伐单抗联合卡培他滨一线治疗老年转移性结直肠癌患者的疗效和安全性
Effect and safety of bevacizumab combined with capecitabine in the treatment of elderly patients with metastatic colorectal cancer
摘要
Abstract
Objective: To evaluate the efficacy and safety of bevacizumab and capecitabine in the first-line treatment of elderly patients with metastatic colorectal cancer (mCRC). Methods: A total of 76 elderly patients with metastatic colorectal cancer first-line treated with (5-7.5 mg/kg, d1, q3w) combined with capecitabine (1000-1250 mg/m2, bid, d1-14, q3w) between January 2013 and December 2016 were collected. The efficacy and adverse events (AEs) were carefully analyzed. Results: After treated with bevacizumab combined with capecitabine, the overall effective rate was 36％ and the disease control rate was 73％. The median progression-free survival and overall survival were 10.6 months and 18.2 months, respectively; 39 patients (51％) developed grade 3 and 4 AE, the most common were hand-foot syndrome (18％), diarrhea (10％) and deep vein thrombosis (7％); four patients died due to treatment-related adverse events. Conclusion: For elderly mCRC patients who are not eligible for multidrug chemotherapy, bevacizumab combined with capecitabine is an effective treatment option.关键词
转移性结直肠癌/联合化疗/老年患者Key words
metastatic colorectal cancer/combined chemotherapy/elderly patients引用本文复制引用
赵磊,王婧,车娟娟,李卉惠,曹邦伟..贝伐单抗联合卡培他滨一线治疗老年转移性结直肠癌患者的疗效和安全性[J].临床与病理杂志,2017,37(8):1629-1633,5.基金项目
北京市优秀人才培养资助 (2014000021469G268),北京友谊医院院启动基金 (yyqdkt 2015-10).This work was supported by the Beijing Talents Fund (2014000021469G268), Rising Star Program from Beijing Friendship Hospital, CMU (yyqdkt 2015-10), China. （2014000021469G268）
